论文部分内容阅读
目的:研究腹腔内注射羟基喜树碱(HCPT)对腹膜腔转移癌模型的疗效和安全性。方法:将高转移性人肝癌细胞株HCCLM3接种于30只裸鼠腹腔内,制成腹膜转移癌模型,随机分为治疗组和对照组各15只;前者组按2 mg/kg剂量腹腔内注射HCPT,后者注射等体积的0.85%氯化钠溶液;于第2,4,6周连续注射7 d,观察8周。监测荷瘤裸鼠的体重和腹膜癌的变化,测量血液学和血清学指标。结果:至研究终点时,治疗组14只裸鼠存活,对照组存活5只;治疗组的平均生存期是(55±1)d(95%CI:54-57 d),对照组的平均生存期是(43±4)d(95%CI:34-51 d)(P=0.002)。治疗组的肿瘤重量明显小于对照组。治疗组未观察到血性腹水和腹腔内弥漫性种植灶,对照组有4只裸鼠出现血性腹水,6只出现腹膜腔内弥漫性种植灶(P<0.001)。外周血白细胞计数在治疗组低于对照组(P<0.05),血清甲胎蛋白浓度在治疗组低于对照组(P<0.05),γ-谷氨酰转肽酶活性在治疗组低于对照组(P<0.05)。两组裸鼠的体重、血常规和血生化其他指标均无统计学差异。未观察到明显的药物相关毒副作用。结论:腹腔内注射HCPT治疗腹膜癌模型,能抑制肿瘤生长,减轻腹膜癌病情,延长荷瘤宿主生存期。
Objective: To study the efficacy and safety of intraperitoneal injection of hydroxycamptothecin (HCPT) in peritoneal cavity metastases model. Methods: HCCLM3 cells were inoculated intraperitoneally into 30 nude mice to establish a model of peritoneal metastasis and were randomly divided into treatment group and control group, 15 rats in each group. The former group was intraperitoneally injected with 2 mg / kg dose HCPT, the latter injected an equal volume of 0.85% sodium chloride solution; in the first 2, 4, 6 weeks of continuous injection of 7 d, observed for 8 weeks. The weight of tumor-bearing nude mice and the changes of peritoneal carcinomas were monitored, and hematological and serological markers were measured. RESULTS: At the end of the study, 14 nude mice survived in the treatment group and five survived in the control group. The mean survival time in the treatment group was (55 ± 1) days (95% CI: 54-57 days), and the mean survival time in the control group The period was (43 ± 4) days (95% CI: 34-51 days) (P = 0.002). The tumor weight of the treatment group was significantly smaller than that of the control group. In the treatment group, bloody ascites and peritoneal disseminated foci were not observed. In the control group, 4 nude mice had bloody ascites and 6 peritoneal diffuse foci (P <0.001). Peripheral blood leukocyte count was lower in the treatment group than in the control group (P <0.05), serum alpha-fetoprotein concentration was lower in the treatment group than in the control group (P <0.05), and γ-glutamyl transpeptidase activity was lower in the treatment group than in the control group Group (P <0.05). Two groups of nude mice weight, blood and blood biochemical other indicators were not statistically different. No significant drug-related side effects were observed. Conclusion: Intraperitoneal injection of HCPT in the treatment of peritoneal cancer model can inhibit tumor growth, reduce the incidence of peritoneal cancer, and prolong the survival of tumor-bearing hosts.